[The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Ohashi
Hirokazu
H
Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Kyoto University.
Takagi
Hitoshi
H
D000419:Albuminuria / Q000188:drug therapy; D000804:Angiotensin II / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000502:physiology; D012160:Retina / Q000378:metabolism; D012307:Risk Factors; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D042461:Vascular Endothelial Growth Factor A; D000804:Angiotensin II; D040262:Receptors, Vascular Endothelial Growth Factor; C081643:candesartan